Igor Puzanov

List of Publications by Citations

225 papers	30,509 citations	60 h-index	174 g-index
251 ext. papers	36,103 ext. citations	8.2 avg, IF	6.6 L-index

#	Paper	IF	Citations
225	Inhibition of mutated, activated BRAF in metastatic melanoma. *New England Journal of Medicine*, **2010**, 363, 809-19	59.2	2871
224	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *New England Journal of Medicine*, **2012**, 367, 1694-703	59.2	2048
223	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, **2018**, 36, 1714-1768	2.2	1740
222	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *New England Journal of Medicine*, **2012**, 366, 707-14	59.2	1697
221	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *Journal of Clinical Oncology*, **2014**, 32, 1020-30	2.2	1684
220	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2015**, 33, 2780-8	2.2	1480
219	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature*, **2010**, 467, 596-9	50.4	1379
218	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *New England Journal of Medicine*, **2015**, 373, 726-36	59.2	1172
217	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncology, The*, **2015**, 16, 908-18	21.7	1151
216	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *New England Journal of Medicine*, **2016**, 375, 1749-1755	59.2	1100
215	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *New England Journal of Medicine*, **2012**, 366, 207-15	59.2	838
214	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncology, The*, **2012**, 13, 459-65	21.7	833
213	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. *Cell*, **2017**, 170, 1109-1119.e10	56.2	762
212	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2012**, 13, 1087-95	21.7	708
211	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *New England Journal of Medicine*, **2018**, 379, 722-730	59.2	659
210	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. *JAMA Oncology*, **2016**, 2, 234-40	13.4	408
209	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet, The*, **2016**, 387, 2008-16	40	374

208	Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. *Journal of Clinical Oncology*, **2016**, 34, 2619-26	2.2	359
207	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. *Journal of Clinical Oncology*, **2018**, 36, 1658-1667	2.2	357
206	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. *Journal of Clinical Oncology*, **2015**, 33, 2013-20	2.2	337
205	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. *Cancer Immunology Research*, **2016**, 4, 959-967	12.5	318
204	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. *New England Journal of Medicine*, **2015**, 373, 428-37	59.2	309
203	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *Journal of Clinical Oncology*, **2013**, 31, 1767-74	2.2	295
202	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. *Oncologist*, **2008**, 13, 1001-11	5.7	273
201	Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. *Journal of Clinical Oncology*, **2009**, 27, 5800-7	2.2	268
200	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 312, 1744-53	27.4	259
199	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. *Nature Communications*, **2016**, 7, 10582	17.4	248
198	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. *Journal of Clinical Oncology*, **2017**, 35, 2535-2541	2.2	244
197	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 378-388	21.7	240
196	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. *Lancet Oncology, The*, **2018**, 19, 405-415	21.7	236
195	Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. *Journal of Clinical Oncology*, **2008**, 26, 2178-85	2.2	212
194	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. *Journal of Clinical Oncology*, **2016**, 34, 871-8	2.2	206
193	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. *Lancet Oncology, The*, **2014**, 15, 954-65	21.7	197
192	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. *JAMA Oncology*, **2018**, 4, 384-388	13.4	191
191	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. *Annals of Surgical Oncology*, **2016**, 23, 4169-4177	3.1	179

190	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. *Cancer*, **2016**, 122, 3354-3362	6.4	164
189	COVID-19 and Cancer: a Comprehensive Review. *Current Oncology Reports*, **2020**, 22, 53	6.3	147
188	Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. *Journal of Clinical Oncology*, **2012**, 30, 1628-34	2.2	141
187	BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. *Journal of Clinical Oncology* , **2018**, 36, 3477-3484	2.2	139
186	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 742-774	7.3	134
185	BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. *Clinical Cancer Research*, **2013**, 19, 6696-702	12.9	122
184	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. *European Journal of Cancer*, **2017**, 86, 37-45	7.5	106
183	Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. *Pigment Cell and Melanoma Research*, **2015**, 28, 611-2	4.5	105
182	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. *Immunotherapy*, **2015** , 7, 611-9	3.8	98
181	Opportunities and obstacles to combination targeted therapy in renal cell cancer. *Clinical Cancer Research*, **2007**, 13, 764s-769s	12.9	95
180	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.. *Journal of Clinical Oncology*, **2017**, 35, 9507-9507	2.2	95
179	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy **2017**, 5, 8		86
178	Treatment of NRAS-mutant melanoma. *Current Treatment Options in Oncology*, **2015**, 16, 15	5.4	86
177	Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. *Oncologist*, **2014**, 19, 616-22	5.7	80
176	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. *Cancer*, **2014**, 120, 2684-93	6.4	79
175	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. *British Journal of Cancer*, **2015**, 113, 1571-80	8.7	76
174	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden **2018**, 6, 32		73
173	A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. *Clinical Cancer Research*, **2015**, 21, 701-11	12.9	73

172	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. *Cancer Immunology Research*, **2015**, 3, 464-9	12.5	71
171	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. *Expert Review of Anticancer Therapy*, **2015**, 15, 1389-403	3.5	70
170	Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.. *Journal of Clinical Oncology*, **2016**, 34, 9568-9568	2.2	68
169	Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. *Journal of Immunotherapy*, **2017**, 40, 31-35	5	62
168	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. *Nature Communications*, **2018**, 9, 3600	17.4	60
167	OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. *Journal of Clinical Oncology*, **2013**, 31, LBA9008-LBA9008	2.2	59
166	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events **2021**, 9,		58
165	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. *European Journal of Cancer*, **2016**, 67, 46-54	7.5	54
164	Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. *Cancer*, **2020**, 126, 3021-3030	6.4	52
163	Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. *European Journal of Cancer*, **2015**, 51, 1435-43	7.5	52
162	Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.. *Journal of Clinical Oncology*, **2014**, 32, 9002-9002	2.2	50
161	H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). *Clinical Cancer Research*, **2013**, 19, 721-30	12.9	47
160	Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers. *Cancer Discovery*, **2020**, 10, 657-663	24.4	46
159	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction **2016**, 4, 60		46
158	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy **2020**, 8,		45
157	Intratumoral Immunotherapy-Update 2019. *Oncologist*, **2020**, 25, e423-e438	5.7	44
156	Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. *Clinical Cancer Research*, **2011**, 17, 3794-802	12.9	43
155	Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. *Journal of Immunotherapy*, **2009**, 32, 181-5	5	43

154	Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2017**, 23, 3601-3609	12.9	42
153	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. *Case Reports in Oncology*, **2019**, 12, 260-276	1	41
152	Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. *Investigational New Drugs*, **2015**, 33, 159-68	4.3	40
151	Molecular targets in melanoma from angiogenesis to apoptosis. *Clinical Cancer Research*, **2006**, 12, 2376s-2383s	12.9	40
150	Combination targeted therapy in advanced renal cell carcinoma. *Cancer*, **2009**, 115, 2368-75	6.4	39
149	B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. *Current Oncology Reports*, **2010**, 12, 146-52	6.3	39
148	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma **2017**, 5, 1		37
147	Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. *Cancer*, **2012**, 118, 6055-62	6.4	37
146	Targeted molecular therapy in melanoma. *Seminars in Cutaneous Medicine and Surgery*, **2010**, 29, 196-201	1.4	36
145	Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).. *Journal of Clinical Oncology*, **2013**, 31, CRA9006-CRA9006	2.2	34
144	Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM).. *Journal of Clinical Oncology*, **2014**, 32, 2511-2511	2.2	34
143	Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9029-9029	2.2	34
142	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study **2014**, 2, 2		33
141	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. *Journal of Molecular Diagnostics*, **2018**, 20, 95-109	5.1	32
140	A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. *Clinical Cancer Research*, **2010**, 16, 348-57	12.9	32
139	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.. *Journal of Clinical Oncology*, **2012**, 30, 8510-8510	2.2	31
138	Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. *Clinical Cancer Research*, **2012**, 18, 3414-27	12.9	29
137	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study **2020**, 8,		28

136	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. *JAMA Oncology*, **2020**, 6, 1256-1264	13.4	27
135	Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. *Clinical Cancer Research*, **2021**, 27, 87-95	12.9	27
134	Clinical characterization of colitis arising from anti-PD-1 based therapy. *OncoImmunology*, **2019**, 8, e1524695	7.2	25
133	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). *Neuro-Oncology*, **2021**, 23, 1961-1973	11	24
132	Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) □ the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). *Journal of Translational Medicine*, **2015**, 13, K8	8.5	23
131	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials **2017**, 5, 72		23
130	Biological challenges of BRAF inhibitor therapy. *Molecular Oncology*, **2011**, 5, 116-23	7.9	23
129	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. *Lancet Oncology, The*, **2021**, 22, 1692-1704	21.7	23
128	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. *European Journal of Cancer*, **2021**, 144, 182-191	7.5	23
127	A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. *Journal of Immunotherapy*, **2013**, 36, 490-5	5	22
126	Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9008a-9008a	2.2	22
125	Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. *Journal of Clinical Oncology*, **2015**, 33, 9063-9063	2.2	22
124	Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.. *Journal of Clinical Oncology*, **2017**, 35, 9509-9509	2.2	22
123	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in -Mutant Melanoma. *Clinical Cancer Research*, **2020**, 26, 46-53	12.9	21
122	Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.. *Journal of Clinical Oncology*, **2016**, 34, 5581-5581	2.2	21
121	mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. *OncoTargets and Therapy*, **2017**, 10, 965-971	4.4	20
120	Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. *Future Oncology*, **2012**, 8, 509-23	3.6	20
119	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.. *Journal of Clinical Oncology*, **2013**, 31, CRA9007-CRA9007	2.2	20

118	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. *Journal of Clinical Oncology*, **2021**, 39, 2914-2925	2.2	20
117	Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. *Circulation: Heart Failure*, **2018**, 11, e004408	7.6	19
116	Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?. *Oncologist*, **2012**, 17, 1534-40	5.7	19
115	Responses to immune checkpoint inhibitors in nonagenarians. *OncoImmunology*, **2016**, 5, e1234572	7.2	19
114	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. *Cancer Immunology Research*, **2016**, 4, 569-73	12.5	18
113	Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. *British Journal of Cancer*, **2019**, 121, 417-420	8.7	17
112	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. *Journal of Clinical Oncology*, **2015**, 33, 3012-3012	2.2	17
111	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. *British Journal of Cancer*, **2020**, 123, 1590-1598	8.7	17
110	Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. *Head and Neck*, **2011**, 33, 1804-8	4.2	16
109	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. *Journal of Clinical Oncology*, **2012**, 30, 8501-8501	2.2	16
108	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. *Nature Communications*, **2021**, 12, 1402	17.4	16
107	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. *JCO Precision Oncology*, **2019**, 3,	3.6	15
106	Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. *Biochemical Pharmacology*, **2010**, 80, 638-46	6	15
105	Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. *Pigment Cell and Melanoma Research*, **2016**, 29, 470-3	4.5	15
104	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. *Cancer Immunology Research*, **2016**, 4, 474-480	12.5	14
103	Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. *Melanoma Research*, **2017**, 27, 585-590	3.3	14
102	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. *JCO Precision Oncology*, **2018**, 2,	3.6	14
101	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. *Clinical Cancer Research*, **2015**, 21, 5215-21	12.9	13

100	Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) **2014**, 2,		13
99	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. *Cancer Medicine*, **2017**, 6, 1904-1914	4.8	13
98	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.. *Journal of Clinical Oncology*, **2012**, 30, 8519-8519	2.2	13
97	A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.. *Journal of Clinical Oncology*, **2018**, 36, 9515-9515	2.2	13
96	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. *Journal of Pain and Symptom Management*, **2018**, 56, 460-472	4.8	13
95	Updated overall survival (OS) results for BRF113220, a phase III study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM).. *Journal of Clinical Oncology*, **2015**, 33, 9036-9036	2.2	12
94	Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).. *Journal of Clinical Oncology*, **2014**, 32, 9010-9010	2.2	11
93	Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma.. *Journal of Clinical Oncology*, **2015**, 33, 9020-9020	2.2	11
92	A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.. *Journal of Clinical Oncology*, **2017**, 35, e14040-e14040	2.2	11
91	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) **2018**, 6, 69		10
90	OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. *Journal of Clinical Oncology*, **2013**, 31, LBA9008-LBA9008	2.2	10
89	Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).. *Journal of Clinical Oncology*, **2018**, 36, 579-579	2.2	10
88	Infectious Colitis Associated With Ipilimumab Therapy. *Gastroenterology Research*, **2014**, 7, 28-31	1.8	10
87	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. *Cancer Discovery*, **2021**, 11, 1996-2013	24.4	10
86	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2016**, 14, 304-313.e6	3.3	10
85	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. *Blood*, **2015**, 126, 4263-4263	2.2	9
84	Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).. *Journal of Clinical Oncology*, **2013**, 31, CRA9006-CRA9006	2.2	9
83	Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.. *Journal of Clinical Oncology*, **2016**, 34, 105-105	2.2	9

82	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.. *Journal of Clinical Oncology*, **2017**, 35, 9074-9074	2.2	9
81	Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. *Journal of Mass Spectrometry*, **2008**, 43, 42-52	2.2	8
80	Managing Metastatic Melanoma in 2022: A Clinical Review.. *JCO Oncology Practice*, **2022**, OP2100686	2.3	8
79	VE-BASKET, a first-in-kind, phase II, histology-independent Basket study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. *Journal of Clinical Oncology*, **2014**, 32, 2533-2533	2.2	8
78	Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).. *Journal of Clinical Oncology*, **2015**, 33, 4507-4507	2.2	8
77	A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.. *Journal of Clinical Oncology*, **2015**, 33, TPS9081-TPS9081	2.2	8
76	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. *Journal of Clinical Oncology*, **2016**, 34, 9513-9513	2.2	8
75	Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-2b in locally/regionally advanced melanoma.. *Journal of Clinical Oncology*, **2018**, 36, 181-181	2.2	8
74	Oncologist uptake of comprehensive genomic profile guided targeted therapy. *Oncotarget*, **2019**, 10, 4616-4629	3.3	8
73	A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma. *Pigment Cell and Melanoma Research*, **2016**, 29, 101-3	4.5	8
72	Challenges faced when identifying patients for combination immunotherapy. *Future Oncology*, **2017**, 13, 1607-1618	3.6	7
71	A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. *Journal of Neuro-Oncology*, **2017**, 133, 435-442	4.8	7
70	A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS).. *Journal of Clinical Oncology*, **2014**, 32, 10503-10503	2.2	7
69	Pembrolizumab for the treatment of advanced melanoma. *Expert Opinion on Orphan Drugs*, **2016**, 4, 867-873	2.1	7
68	Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. *British Journal of Clinical Pharmacology*, **2018**, 84, 112-121	3.8	6
67	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.. *Journal of Clinical Oncology*, **2012**, 30, 4117-4117	2.2	6
66	A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).. *Journal of Clinical Oncology*, **2016**, 34, TPS9598-TPS9598	2.2	6
65	Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9026-9026	2.2	5

64	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.. *Journal of Clinical Oncology*, **2015**, 33, 9019-9019	2.2	5
63	A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.. *Journal of Clinical Oncology*, **2019**, 37, 9586-9586	2.2	5
62	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. *European Journal of Cancer*, **2021**, 145, 1-10	7.5	5
61	Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.. *Journal of Clinical Oncology*, **2012**, 30, 4545-4545	2.2	4
60	Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.. *Journal of Clinical Oncology*, **2017**, 35, 9566-9566	2.2	4
59	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**, 27, 3317-3328	12.9	4
58	Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab. *OncoTargets and Therapy*, **2020**, 13, 4021-4034	4.4	3
57	The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. *Journal of Translational Medicine*, **2018**, 16, 101	8.5	3
56	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. *Expert Review of Dermatology*, **2013**, 8, 479-487		3
55	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. *Blood*, **2016**, 128, 480-480	2.2	3
54	Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2012**, 30, 4506-4506	2.2	3
53	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. *Journal of Clinical Oncology*, **2015**, 33, 3068-3068	2.2	3
52	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. *Clinical Cancer Research*, **2020**, 26, 5598-5608	12.9	3
51	Neoadjuvant Pembrolizumab and High-Dose IFN□-2b in Resectable Regionally Advanced Melanoma. *Clinical Cancer Research*, **2021**, 27, 4195-4204	12.9	3
50	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). *Melanoma Management*, **2020**, 7, MMT41	2.1	2
49	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 **2019**, 7, 221		2
48	Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. *Anti-Cancer Drugs*, **2015**, 26, 785-92	2.4	2
47	Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101) **2019**,		2

46	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608.. *Journal of Clinical Oncology*, **2013**, 31, CRA9007-CRA9007	2.2	2
45	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9006-9006	2.2	2
44	Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.. *Journal of Clinical Oncology*, **2015**, 33, 4508-4508	2.2	2
43	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. *Journal of Clinical Oncology*, **2015**, 33, 9040-9040	2.2	2
42	Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.. *Journal of Clinical Oncology*, **2019**, 37, 9524-9524	2.2	2
41	A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors		2
40	Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis **2021**, 9,		2
39	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors **2021**, 9,		2
38	Oncolytic Viruses: T-VEC and Others **2018**, 387-403		1
37	The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs. *JAMA Dermatology*, **2019**, 155, 862-863	5.1	1
36	Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.. *Journal of Clinical Oncology*, **2014**, 32, 9075-9075	2.2	1
35	Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma.. *Journal of Clinical Oncology*, **2016**, 34, 9516-9516	2.2	1
34	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. *Journal of Clinical Oncology*, **2017**, 35, 2004-2004	2.2	1
33	Comprehensive immune and mutational profile of melanoma.. *Journal of Clinical Oncology*, **2018**, 36, 182-182	2.2	1
32	Immune deserts: Correlation of low CD8 gene expression with non-response to checkpoint inhibition.. *Journal of Clinical Oncology*, **2018**, 36, 23-23	2.2	1
31	Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).. *Journal of Clinical Oncology*, **2020**, 38, 10029-10029	2.2	1
30	Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.. *Journal of Clinical Oncology*, **2020**, 38, 5080-5080	2.2	1
29	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. *Kidney Cancer Journal: Official Journal of the Kidney Cancer Association*, **2021**, 19, 64-72	0.1	1

28	A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).. *Journal of Clinical Oncology*, **2018**, 36, TPS219-TPS219	2.2	1
27	The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019 **2020**, 8,		1
26	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. *Journal of Translational Medicine*, **2021**, 19, 142	8.5	1
25	Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.. *Journal of Clinical Oncology*, **2021**, 39, 2568-2568	2.2	1
24	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). *Journal of Translational Medicine*, **2021**, 19, 238	8.5	1
23	Toxicities in Immune Checkpoint Inhibitors **2019**, 205-226		1
22	The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. *Journal of Translational Medicine*, **2020**, 18, 171	8.5	1
21	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). *Journal of Translational Medicine*, **2021**, 19, 13	8.5	1
20	Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors.. *Journal of Clinical Oncology*, **2015**, 33, e20045-e20045	2.2	0
19	Effect of CTLA-4 overexpression on response to ipilimumab in melanoma.. *Journal of Clinical Oncology*, **2018**, 36, 190-190	2.2	0
18	Correlation of lung cancer mutational profile with immune profile.. *Journal of Clinical Oncology*, **2018**, 36, 146-146	2.2	0
17	Treatment of elderly patients with melanoma. *Memo - Magazine of European Medical Oncology*, **2016**, 9, 13-16	0.3	
16	Talimogene laherparepvec in advanced melanoma. *Expert Opinion on Orphan Drugs*, **2016**, 4, 781-788	1.1	
15	Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors. *Memo - Magazine of European Medical Oncology*, **2012**, 5, 302-308	0.3	
14	Trial in progress: A phase 2 study of intratumor pil-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV mealanoma progressing on either pembrolizumab or nivolumab treatment (PISCES).. *Journal of Clinical Oncology*, **2018**, 36, TPS9601-TPS9601	2.2	
13	Cardivascular Toxicities of Immunotherapy **2020**, 259-276		
12	Identifying strategies to address obstacles to optimal integration of cancer immunotherapies in the community.. *Journal of Clinical Oncology*, **2020**, 38, 96-96	2.2	
11	Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.. *Journal of Clinical Oncology*, **2014**, 32, 11089-11089	2.2	

10	A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2014**, 32, 4570-4570	2.2
9	Thyroid nodule: not as clear-cut as it seems. *Journal of Community and Supportive Oncology*, **2016**, 14, 45-8	
8	Comprehensive echocardiographic assessment of cardiac function in patients with metastatic renal cell carcinoma newly initiated on sunitinib.. *Journal of Clinical Oncology*, **2016**, 34, e16072-e16072	2.2
7	Risk of left ventricular systolic dysfunction with sunitinib therapy in patients with metastatic renal cell carcinoma: A prospective cohort study.. *Journal of Clinical Oncology*, **2016**, 34, e16104-e16104	2.2
6	Anti-PD-1 in patients with advanced malignancies and baseline organ dysfunction.. *Journal of Clinical Oncology*, **2016**, 34, e14539-e14539	2.2
5	Cyclooxygenase inhibition and response to anti-PD1/L1 in advanced melanoma.. *Journal of Clinical Oncology*, **2016**, 34, e21023-e21023	2.2
4	The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. *Journal of Translational Medicine*, **2021**, 19, 144	8.5
3	Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy. *American Journal of Cancer Research*, **2021**, 11, 5190-5213	4.4
2	The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. *Journal of Translational Medicine*, **2022**, 20, 179	8.5
1	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.. *Journal of Translational Medicine*, **2022**, 20, 200	8.5